CLINICAL_TRIALS
trial_result
· 2021-03-10
Clinical Trial Update: Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia [Phase 4]
Summary
Phase 4 trial update on the persistence of effect and safety of valbenazine for tardive dyskinesia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia (TD) | Phase 4 | Status: COMPLETED | Results posted: 2021-03-10